Business

United States

Sam Altman's longevity startup is upping the dose in an Alzheimer's drug trial after a lackluster first round

Business Insider

Aug 26, 2026 · 9:21 PM

0 views

Sam Altman's longevity startup is upping the dose in an Alzheimer's drug trial after a lackluster first round

The Sam Altman-backed longevity biotech company is upping the dose of its experimental Alzheimer's drug in clinical trials.

Continue Reading on Business Insider

This article is aggregated from Business Insider. Click below to read the full story.

Read Full Story

🏷️ Topics: altmans longevity startup upping alzheimers trial lackluster round

🔗 Share this story

Twitter Facebook WhatsApp LinkedIn

Related Stories

Stanley Druckenmiller's AI writing has split Wall Street down the middle

Stanley Druckenmiller's AI writing has split Wall Street down the middle

Business Insider 4m ago

CityPickle Rides Pickleball Boom

CityPickle Rides Pickleball Boom

Bloomberg 9m ago

Australia's social media ban for teens is going, uh, pretty badly

Australia's social media ban for teens is going, uh, pretty badly

Business Insider 12m ago

ChatGPT expands its foothold in the nation's classrooms

ChatGPT expands its foothold in the nation's classrooms

Business Insider 15m ago

I raised 5 kids and refused to spend thousands on youth sports. I don't regret it.

I raised 5 kids and refused to spend thousands on youth sports. I don't regret it.

Business Insider 17m ago

Prince Harry and Meghan Markle's new UK address

Prince Harry and Meghan Markle's new UK address

Economic Times 21m ago